New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 6, 2014
13:04 EDTLOXOJames Flynn reports 9.98% passive stake in Loxo Oncology
News For LOXO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 2, 2015
06:47 EDTLOXOLoxo Oncology announces 2015 program guidance
Loxo Oncology provided updated 2015 program guidance and unveiled molecular targets for three of its active preclinical programs. The three targets disclosed are Rearranged during Transfection, Fibroblast Growth Factor Receptor, and FMS-Like Tyrosine kinase 3. In addition to these three programs, Loxo possesses well-vetted candidates for two other programs, not yet disclosed by target name, that are ready for IND-enabling work. Like Loxo's clinical program LOXO-101, these preclinical pipeline programs are the result of Loxo's collaboration with Array BioPharma. The Company will provide periodic data updates for its discovery pipeline at medical meetings, beginning in the second half of 2015. Loxo continues to advance LOXO-101, a selective inhibitor of the TRK family of tyrosine kinase receptors. LOXO-101 is currently in a Phase 1 dose-escalation clinical trial, for which initial safety and pharmacokinetic data will be presented in April at the American Association of Cancer Research 2015 Annual Meeting. As per its collaboration agreement with Array BioPharma, Loxo initially held exclusivity for twelve undisclosed targets, excluding TRK. In January 2015, Loxo's exclusivity was reduced to seven targets, and will be further reduced to four targets in January 2016. Loxo has an option for a fifth target, which would trigger a milestone payment to Array.
February 25, 2015
10:03 EDTLOXOLoxo Oncology to host conference call
Conference call to discuss the company's program guidance for 2015 will be held on March 3 at 8 am. Webcast Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use